+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action

  • PDF Icon

    Report

  • 330 Pages
  • August 2022
  • Region: Global
  • The Insight Partners
  • ID: 5659422
The global glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.

The report highlights prevailing trends and factors driving the market growth.The demand for glycomic therapeutics is attributed to a wide application of glycan-based drugs followed by the development of new treatment processes, increasing research and development in the field of glycomic therapeutics, and rising usage of glycomics-based therapeutics in various diseases leading to the development of new treatment processes.

Wide Application to Treat Various Diseases Followed by Development of New Treatment Processes

Glycan-based therapeutics have wide applications in the pharmaceutical industry; the products are available in different structures & forms and developed as per the application. It is designed for various diseases, such as thrombosis, anemia, cancer, influenza, cataract, and antiinflammation.

The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used across the globeand are part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. Due to its known neuroprotective effects, EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models.

The largest and fastest-growing glycomic application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in research institutions. For instance, In April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule in cancer cells. The protein might revolutionize the area associated with cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative encourages research institutes to dive into establishing cutting-edge technologies, methods, and platforms that expedite drug discovery and development. Merck, a CQDM member, is financing the studies. The University of Alberta and 48HD will work together on the CQDM Quantum Leap initiative project. Additionally, GlycoNet - a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, provides the funds to enhance Canadians' quality of life.
  • In December 2021, researchers at Griffith University’s Institute for Glycomics received US$ 2.6 million in funding from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. This has boosted their fight against cancer.
  • In January 2022, the National Health and Medical Research Council (NHMRC) gave researchers from the Institute of Glycomics grants of more than US$ 1.1 million to help them create new medicines to treat multidrug-resistant gonorrhea infections.
  • In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing preclinical outcomes.
Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). Further, the administration of microbiome-mediating glycans could radically improve the treatment of IBD sufferers who do not respond to the current standard of care and other patients who have autoimmune and inflammatory conditions by 16%.
These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for various diseases is driving the glycomic therapeutics market.

Based on class, the glycomic therapeutics market is bifurcated into isolated and synthetic. Based on structures, the glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglcans, glycophosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. Based on indication, the glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anemia, anti-adhesive & anti-inflammatory, cataract, Gaucher’s diseases, MPS-1 & IV, cancer, Alzheimer’s disease, influenza type A & B, and others. Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others.

Impact of COVID-19 Pandemic on Glycomic Therapeutics Market

The overall impact of the COVID-19 pandemic on the European glycomic therapeutics market was mixed, and the market regained traction and is expected to grow in the coming years. Pharmaceutical and biotechnology companies invested a huge amount in producing several pipeline products that can effectively combat the spread of SARS-CoV-2.

The onset of the COVID-19 pandemic positively impacted the glycomic therapeutics market. Pharmaceutical and biotechnology companies invested a huge amount in producing several pipeline products that can effectively combat the spread of SARS-CoV-2. Moreover, during the pandemic, the demand for the development of new drugs and vaccines increased to tackle COVID-19 in patients suffering from several other diseases. The increased number of researches led to high utilization of technology instead of human resource to prevent the spread of SARS-CoV-2. Furthermore, governments of Asia Pacific countries organized programs and open challenge events for researchers to develop innovative drugs for the treatment of COVID-19. Such events increased the overall number of research on COVID-19 owing to increased government funding.

Thus, the above-mentioned factors indicate the overall positive impact on the glycomic therapeutics market during the forecast period.
Although elective surgeries resumed in the UK and many other countries in mid-2020, most hospitals were functioning at considerably reduced capacity, which translates to an ever-growing waitlist. As of September 2020, ~140,000 patients in England alone had been waiting more than a year for their surgeries - 100 times the number in 2019. And with a new, highly transmissible variant of SARS-CoV-2 circulating in the UK that has resulted in a third national lockdown and further appointment cancellations, patients are now facing longer waits. Further, according to the National Library of Medicine, the decline in COVID-19 cases after the third wave of the COVID-19 pandemic grew to 51% for ophthalmic procedures, 68% for pain procedures, and 49% for orthopedic procedures. The number of electoral processes conducted increased in the EU but was still below pre-pandemic standards. In contrast, during the COVID-19 pandemic, a generic trend toward reduced numbers of nonelective, emergency neurosurgical cases in countries such as Austria, Switzerland, and the Czech Republic was observed. This was majorly driven by a decreased incidence of conditions commonly associated with traumatic aetiologies, including brain injuries, spine conditions, and chronic subdural hematomas. Despite the challenges of delivering health services and intensive care during the COVID-19 pandemic, data indicated that emergency care could still be provided in these countries.

Various organic and inorganic strategies are adopted by companies operating in the global glycomic therapeutics market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few significant developments by key players operating in the global glycomic therapeutics market are listed below.
  • In May 2022, Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc., with an aim to create specialty products.
  • In March 2022, Halozyme Therapeutics announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gave exclusive access to Halozyme's ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target.

A few major primary and secondary sources that were considered while preparing the report on the global glycomic therapeutics market are the American Medical Association, the British Journal of Surgery, and the National Library of Medicine.

Table of Contents

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Glycomic Therapeutics Market - By Class
1.3.2 Global Glycomic Therapeutics Market - By Structures
1.3.3 Global Glycomic Therapeutics Market - By Indications
1.3.4 Global Glycomic Therapeutics Market - By Mode of Action
1.3.5 Global Glycomic Therapeutics Market - By Geography
2. Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Glycomic Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East & Africa - PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinion
5. Glycomic Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market- Global Analysis
6.1 Global Glycomic Therapeutics Market Revenue Forecast and Analysis
6.1.1 Global Glycomic Therapeutics Market Revenue Forecast and Analysis
6.1.2 Global Glycomic Therapeutics Market - Market Potential Analysis, By Region
6.2 Company Analysis
6.2.1 Growth Strategy Analysis
6.2.2 Performance of Key Players
6.2.2.1 Genzyme Corporation (Sanofi)
6.2.2.2 GlaxoSmithKline plc.
6.3 Glycan-Based Drugs in Clinical Trial Phases
7. Global Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
7.1 Overview
7.2 Global Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.3 Isolated
7.3.1 Overview
7.3.2 Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 Synthetic - Revenue and Forecast to 2028 (US$ Million)
8. Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
8.1 Overview
8.2 Global Glycomics Market, By Indication 2022 & 2028 (%)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher’s diseases
8.7.1 Overview
8.7.2 Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer's
8.10.1 Overview
8.10.2 Alzheimer's Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others Revenue and Forecast to 2028 (US$ Million)
9. Global Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
9.1 Overview
9.2 Global Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.3.2 Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.4.4 Oseltamivir
9.4.4.1 Overview
9.4.4.2 Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 Heparin - Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 Laronidase - Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Agalsidase (Fabrazyme)
9.8.4.1 Overview
9.8.4.2 Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.5 N-butyl-deoxynojirimycin (DNJ)
9.8.5.1 Overview
9.8.5.2 N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.6 Others
9.8.6.1 Overview
9.8.6.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 Acarbose - Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Alglucosidase Alfa (Myozyme)
9.9.4.1 Overview
9.9.4.2 Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.9.5 Allosamidin
9.9.5.1 Overview
9.9.5.2 Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)
9.9.6 Others
9.9.6.1 Overview
9.9.6.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
10. Global Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
10.1 Overview
10.2 Global Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Geographical Analysis
11.1 North America: Glycomic Therapeutics Market
11.1.1 Overview
11.1.2 North America: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3 North America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.4 North America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.4.1 North America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.4.2 North America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.4.3 North America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.4.4 North America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.5 North America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.6 North America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.7 North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.1.8 US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.8.1.1 Overview
11.1.8.1.2 US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.8.1.3 US: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.8.1.4 US: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.8.1.4.1 US: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.8.1.4.2 US: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.8.1.4.3 US: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.8.1.4.4 US: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.8.1.5 US: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.8.1.6 US: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.8.2 Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.8.2.1 Overview
11.1.8.2.2 Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.8.2.3 Canada: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.8.2.4 Canada: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.8.2.4.1 Canada: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.8.2.4.2 Canada: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.8.2.4.3 Canada: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.8.2.4.4 Canada: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.8.2.5 Canada: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.8.2.6 Canada: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.8.3 Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.8.3.1 Overview
11.1.8.3.2 Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.8.3.3 Mexico: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.8.3.4 Mexico: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.8.3.4.1 Mexico: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.8.3.4.2 Mexico: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.8.3.4.3 Mexico: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.8.3.4.4 Mexico: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.8.3.5 Mexico: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.8.3.6 Mexico: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2 Europe: Glycomic Therapeutics Market
11.2.1 Overview
11.2.2 Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.3 Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.4 Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.4.1 Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.4.2 Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.2.4.3 Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.2.4.4 Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.5 Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.6 Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2.7 Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.2.7.1 Germany: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.1.1 Overview
11.2.7.1.2 Germany: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.1.3 Germany: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.7.1.4 Germany: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.7.1.4.1 Germany: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.7.1.4.2 Germany: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.2.7.1.4.3 Germany: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.2.7.1.4.4 Germany: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.7.1.5 Germany: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.7.1.6 Germany: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2.7.2 UK: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.2.1 Overview
11.2.7.2.2 UK: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.2.3 UK: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.7.2.4 UK: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.7.2.4.1 UK: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.7.2.4.2 UK: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.2.7.2.4.3 UK: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.2.7.2.4.4 UK: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.7.2.5 UK: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.7.2.6 UK: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2.7.3 France: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.3.1 Overview
11.2.7.3.2 France: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.3.3 France: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.7.3.4 France: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.7.3.4.1 France: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.7.3.4.2 France: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.2.7.3.4.3 France: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.2.7.3.4.4 France: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.7.3.5 France: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.7.3.6 France: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2.7.4 Italy: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.4.1 Overview
11.2.7.4.2 Italy: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.4.3 Italy: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.7.4.4 Italy: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.7.4.4.1 Italy: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.7.4.4.2 Italy: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.2.7.4.4.3 Italy: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.2.7.4.4.4 Italy: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.7.4.5 Italy: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.7.4.6 Italy: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2.7.5 Spain: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.5.1 Overview
11.2.7.5.2 Spain: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.5.3 Spain: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.7.5.4 Spain: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.7.5.4.1 Spain: Glycomic Therapeutics Market, by Targeting Glycosphingolipid, 2019-2028 (US$ Million)
11.2.7.5.4.2 Spain: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.7.5.4.3 Spain: Glycomic Therapeutics Market, by Targeting Glycosaminoglycans, 2019-2028 (US$ Million)
11.2.7.5.4.4 Spain: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.7.5.5 Spain: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.7.5.6 Spain: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.2.7.6 Rest of Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.6.1 Overview
11.2.7.6.2 Rest of Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.2.7.6.3 Rest of Europe: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.2.7.6.4 Rest of Europe: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.2.7.6.4.1 Rest of Europe: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.2.7.6.4.2 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.2.7.6.4.3 Rest of Europe: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.2.7.6.4.4 Rest of Europe: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.2.7.6.5 Rest of Europe: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.2.7.6.6 Rest of Europe: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.3 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts To 2028
11.3.1 Overview
11.3.2 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.4 Asia Pacific: Glycomic Therapeutics Market, by Structures, 2019-2028 (US$ Million)
11.3.4.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.4.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.4.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.4.4 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.5 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.6 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.3.7 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)
11.3.7.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.1.1 Overview
11.3.7.1.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.1.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.7.1.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US$ Million)
11.3.7.1.4.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.7.1.4.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.7.1.4.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.7.1.4.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.7.1.5 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.7.1.6 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.3.7.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.2.1 Overview
11.3.7.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.2.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.7.2.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US$ Million)
11.3.7.2.4.1 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.7.2.4.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.7.2.4.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.7.2.4.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.7.2.5 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.7.2.6 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.3.7.3 India Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.3.1 Overview
11.3.7.3.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.3.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.7.3.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US$ Million)
11.3.7.3.4.1 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.7.3.4.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.7.3.4.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.7.3.4.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.7.3.5 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.7.3.6 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.3.7.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.4.1 Overview
11.3.7.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.7.4.4 South Korea: Glycomic Therapeutics Market, by Structures, 2019-2028 (US$ Million)
11.3.7.4.4.1 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.7.4.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.7.4.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.7.4.4.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.7.4.5 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.7.4.6 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.3.7.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.5.1 Overview
11.3.7.5.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.3.7.5.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.7.5.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US$ Million)
11.3.7.5.4.1 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.7.5.4.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.7.5.4.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.7.5.4.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.7.5.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.7.5.6 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.3.7.6 Rest of Asia Pacific: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.6.1 Overview
11.3.7.6.2 Rest of Asia Pacific: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.3.7.6.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.3.7.6.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US$ Million)
11.3.7.6.4.1 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.3.7.6.4.2 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.3.7.6.4.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.3.7.6.4.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.3.7.6.5 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.3.7.6.6 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.4 Middle East & Africa: Glycomic Therapeutics Market
11.4.1 Overview
11.4.2 Middle East & Africa: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.4.3 Middle East & Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.4.4 Middle East & Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.4.4.1 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.4.4.2 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.4.4.3 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.4.4.4 Middle East & Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.4.5 Middle East & Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.4.6 Middle East & Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.4.7 Middle East & Africa: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.4.7.1 Saudi Arabia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.4.7.1.1 Overview
11.4.7.1.2 Saudi Arabia: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.1.3 Saudi Arabia: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.4.7.1.4 Saudi Arabia: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.4.7.1.4.1 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.4.7.1.4.2 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.4.7.1.4.3 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.4.7.1.4.4 Saudi Arabia: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.4.7.1.5 Saudi Arabia: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.4.7.1.6 Saudi Arabia: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.4.7.2 UAE: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.4.7.2.1 Overview
11.4.7.2.2 UAE: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.2.3 UAE: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.4.7.2.4 UAE: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.4.7.2.4.1 UAE: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.4.7.2.4.2 UAE: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.4.7.2.4.3 UAE: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.4.7.2.4.4 UAE: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.4.7.2.5 UAE: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.4.7.2.6 UAE: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.4.7.3 South Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.4.7.3.1 Overview
11.4.7.3.2 South Africa: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.3.3 South Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.4.7.3.4 South Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.4.7.3.4.1 South Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.4.7.3.4.2 South Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.4.7.3.4.3 South Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.4.7.3.4.4 South Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.4.7.3.5 South Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.4.7.3.6 South Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.4.7.4 Rest of Middle East and Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.4.7.4.1 Overview
11.4.7.4.2 Rest of MEA: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.4.7.4.3 Rest of MEA: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.4.7.4.4 Rest of MEA: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.4.7.4.4.1 Rest of MEA: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.4.7.4.4.2 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.4.7.4.4.3 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.4.7.4.4.4 Rest of MEA: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.4.7.4.5 Rest of MEA: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.4.7.4.6 Rest of MEA: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.5 South & Central America: Glycomic Therapeutics Market
11.5.1 Overview
11.5.2 South & Central America: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.5.3 South & Central America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.5.4 South & Central America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.5.4.1 South & Central America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.5.4.2 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.5.4.3 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.5.4.4 South & Central America: G
List of Figures
Figure 1. Glycomic Therapeutics Market Segmentation
Figure 2. Glycomic Therapeutics Market, By Region
Figure 3. Global Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in Glycomic Therapeutics Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Glycomic Therapeutics Market, by Geography (US$ Million)
Figure 7. Global Glycomic Therapeutics Market - Leading Country Markets (US$ Million)
Figure 8. Global Glycomic Therapeutics Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East & Africa: PEST Analysis
Figure 13. South & Central America: PEST Analysis
Figure 14. Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 15. Global Glycomics market - Revenue Forecast And Analysis - 2020- 2028
Figure 16. Global Glycomic Therapeutics Market - Revenue Forecast and Analysis - 2022 - 2028
Figure 17. Global Glycomic Therapeutics Market - Market Potential Analysis, By Region
Figure 18. Market Positioning of Key Players in Glycomic Therapeutics Market
Figure 19. Global Glycomic Therapeutics Market - Growth Strategy Analysis
Figure 20. Global Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 21. Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Synthetic - Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Global Glycomics Market, by Indication 2022 & 2028 (%)
Figure 24. Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Gaucher’s diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 29. MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 30. Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 31. Alzheimer's Revenue and Forecasts to 2028 (US$ Million)
Figure 32. Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Others Revenue and Forecasts to 2028 (US$ Million)
Figure 34. Global Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 35. Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. 8.4.5.2 Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. Heparin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. Inflammatory Myopathies - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Guillain-Barre Syndrome - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 48. Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Imiglucerase (Cerezyme - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 52. Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 53. Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 54. Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 55. Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 56. Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 57. Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 58. Global Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 59. Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 60. Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 61. Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 62. Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 63. Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 64. Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 65. Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 66. Others - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 67. North America: Glycomic Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 68. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Million)
Figure 69. North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 70. US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 72. Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. Europe: Glycomic Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 74. Europe Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Million)
Figure 75. Europe: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 76. Germany: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 77. UK: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 78. France: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 79. Italy: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 80. Spain: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 81. Rest of Europe: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 82. Asia Pacific: Glycomic Therapeutics Market Overview, by Country (2022)
Figure 83. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 84. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)
Figure 85. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 86. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 87. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 88. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 89. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 90. Rest of Asia Pacific: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 91. Middle East & Africa Glycomic Therapeutics Market Revenue Overview, by Country, 2022 (US$ Million)
Figure 92. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Million)
Figure 93. Middle East & Africa: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 94. Saudi Arabia: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 95. UAE: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 96. South Africa: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 97. Rest of MEA: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 98. South and Central America: Glycomic Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 99. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Million)
Figure 100. South & Central America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 101. Brazil: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 102. Argentina: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 103. Rest of SCAM: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 104. Impact of COVID-19 Pandemic in North American Country Markets
Figure 105. Impact of COVID-19 Pandemic in Europe Country Markets
Figure 106. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 107. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets
Figure 108. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 109. Growth Strategies in the Glycomic Therapeutics Market (%)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Intellihep Ltd
  • Protalix Biotherapeutics
  • BioMarin Pharmaceutical Inc.
  • Genzyme Corporation (Sanofi)
  • Halozyme Therapeutics, Inc.
  • Bayer AG
  • Alzheon, Inc.
  • GlycoMar
  • GlaxoSmithKline plc-
  • F- Hoffmann-La Roche Ltd

Table Information